A benzoxazole derivative PO‐296 inhibits T lymphocyte proliferation by the JAK3/STAT5 signal pathway

• Published in: Journal of cellular biochemistry Vol. 120; no. 6; pp. 9193 - 9202
• Main Authors: Luo, Xing‐yan, Zhou, Hong, Wang, Si‐yu, Xiong, Jing, Mo, Chun‐fen, Guo, Hui‐jie, Wang, Yan‐tang, Yang, Shu‐xia, Li, Li‐mei, Zou, Qiang, Liu, Yang
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.06.2019
• Subjects: 1-Phosphatidylinositol 3-kinase; [2‐(6‐chlorobenzo[d]oxazol‐2‐yl)‐4,5,6,7‐tetrahydro‐2H‐indazol‐3‐ol] (PO‐296); AKT protein; Autoimmune diseases; CD69 antigen; Cytotoxicity; G1 phase; Immunosuppressive activity; Immunosuppressive agents; Interferon; Interleukins; Janus kinase; Janus kinase 3; Kinases; Lead compounds; Lymphocytes; Lymphocytes T; Medical treatment; Oxazol; Phosphorylation; Proteins; Stat5 protein; T lymphocyte proliferation; Toxicity; Transcription; [2-(6-chlorobenzo[d]oxazol-2-yl)-4,5,6,7-tetrahydro-2H-indazol-3-ol] (PO-296); Immunosuppressive activity; T lymphocyte proliferation

Immunosuppressants have shown striking achievements in treating autoimmune diseases in recent years. It is urgent to develop more immunosuppressants to provide more options for patients. PO‐296 [2‐(6‐chlorobenzo[d]oxazol‐2‐yl)‐4,5,6,7‐tetrahydro‐2H‐indazol‐3‐ol] was identified as a novel benzoxazole...